Skip to main content

The Globe and Mail

Ukraine approves Valeant’s purchase of Obagi

Valeant Pharmaceuticals International Inc. CEO Michael Pearson is seen in one of the company’s laboratories in Laval.


Valeant Pharmaceuticals International Inc. says Ukraine's anti-monopoly committee has given its approval for the Montreal-based company to buy Obagi Medical Products Inc.

Valeant has offered $24 (U.S.) per share for Obagi or about $418-million.

The drug company said Wednesday it does not expect to further extend its offer beyond the current deadline of midnight Thursday night.

Story continues below advertisement

Valeant said earlier this week that it had cleared a U.S. regulatory hurdle, with the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

The company beat out German company Merz Pharma Group which had offered $22 per share, but dropped out of the bidding earlier this month.

Valeant, formerly Biovail Corp., develops, manufactures and sells a range of neurology, dermatology and branded generic drugs.

Report an error

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨